Abstract
Semaglutide is a glucagon-like peptide-1 receptor-agonist (GLP-1 RA), which is injected subcutaneously once a week for treatment of Type 2 diabetes. In this review, the present results of semaglutide treatment are presented. Semaglutide has been evaluated in more than 8,000 patients across the spectrum of Type 2 diabetes. Trials with semaglutide have demonstrated superiority with sustained improved glycaemic control and weight loss compared to oral antidiabetic agents, other GLP-1 RAs and basalinsulin. In addition, semaglutide significantly decreased the occurrence of cardiovascular events compared with standard pharmacological diabetic treatment combined with placebo.
| Translated title of the contribution | The glucagon-like peptide-1 receptor-agonist semaglutide |
|---|---|
| Original language | Danish |
| Article number | V03190155 |
| Journal | Ugeskrift for Laeger |
| Volume | 181 |
| Number of pages | 5 |
| ISSN | 0041-5782 |
| Publication status | Published - 2019 |